Novel KRAS Inhibitor Leads to Durable Responses in Multiple Tumor Types

(MedPage Today) -- A new-generation KRAS G12C inhibitor induced responses in more than half of patients with previously treated non-small cell lung cancer (NSCLC) harboring the mutation, a subgroup analysis of a phase I trial showed. In 58 patients...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news